BioMedNewsBreaks Archive - Page 61 of 241

FridayJun 07, 2024 1:49 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company announced today that on June 5, 2024, it received a formal notification from the Listing Qualification Department of the Nasdaq Stock Market that it has regained compliance with the minimum $1.00 bid price requirement outlined in Nasdaq Listing Rule 5550(a)(2). The notification further stated that Scinai remains non-compliant with the equity requirement in Listing Rule 5550(b)(1) or any of the alternative requirements under Listing Rule 5550(b). Accordingly, on June 18, 2024,…

WednesdayJun 05, 2024 3:58 pm

BioMedNewsBreaks — Bluejay Diagnostics Inc. (NASDAQ: BJDX) Secures ~$2.2M in Private Placement

Bluejay (NASDAQ: BJDX) is a medical diagnostics company that offers the Symphony technology platform, Symphony Cartridge and tests and testing devices for the diagnosis of allergic conjunctivitis and monitoring of disease progression in critical care settings. Aegis Capital Corp. announced that it acted as exclusive placement agent on a ~$2.2 million private placement for Bluejay Diagnostics. To view the Form 8-K filing, visit https://ibn.fm/3xAyc About Bluejay Diagnostics Inc. Bluejay operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force;…

WednesdayJun 05, 2024 3:49 pm

BioMedNewsBreaks — Astiva Health Inc. to Host Summer Gala

Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan dedicated to reshaping personalized and comprehensive healthcare, today announced the Astiva Health Summer Gala, to be held at its headquarters in Orange, California. The event marks a significant milestone for the company and is slated to take place from 5 p.m. to 10 p.m. PT on June 29, 2024. The gala will feature live music, a dynamic atmosphere, as well as an important announcement concerning the company’s future plans. A keynote address by Astiva Health’s executive team will highlight strategic initiatives as the company continues its journey towards excellence…

WednesdayJun 05, 2024 2:34 pm

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Emerging Growth Conference

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has announced that management will present at the Emerging Growth Conference. Clene’s presentation is slated to begin at 2:20 p.m. on June 12, 2024, and include a corporate presentation with questions and-answers. Interested parties can visit https://ibn.fm/A217J to register for and view the webcast, which will also be available on the Events section of the Clene website. A replay of the presentation will be available as detailed…

WednesdayJun 05, 2024 12:51 pm

BioMedNewsBreaks — HealthLynked Corp. (HLYK) Receives $1M from CEO to Support Company’s Efforts to ‘Lead the Way’ to More Efficient Healthcare System

HealthLynked (OTCQB: HLYK), a leader in personalized healthcare and patient-centric services, has received $1 million in financing from CEO Dr. Michael Dent, which will provide additional capital so the company can expand its offerings and accelerate its growth. A visionary in the healthcare industry, Dent has been at the helm of HealthLynked as it has developed services designed to enhance the patient experience and improve healthcare outcomes. HealthLynked services include online scheduling for doctors nationwide, personal medical record storage, telemedicine, nurse chat, a rewards points program, an e-commerce platform for more than 15,000 name-brand medical supplies, comanagement of family members'…

WednesdayJun 05, 2024 10:14 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Event Spotlighting Lead Drug Candidate

Annovis Bio (NYSE: ANVS), a late-stage, clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”) will host an investor webcast. According to the announcement, during the webcast, Annovis Bio officials will discuss recent advancements in the development of Buntanetap, the company’s lead drug candidate, as well as strategic plans for upcoming clinical trials and an overview of the company’s progress along with its future direction. The call is slated for June 11, 2024, at 4:30 p.m. ET. Buntanetap has been formulated to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including…

MondayJun 03, 2024 3:49 pm

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Releases Q1 2024 Quarterly Report

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceuticals and technology, is reporting its first-quarter 2024 revenues. According to the report, the company saw revenues of $408,532 while also strengthening its balance sheet with the completion of an $8.4 million private placement involving existing and new shareholders; shares for the placement were offered at $4 per share. Nutriband also reported a cash position of $8,347,739. In the report, the company observed that it been focused on using penetration pricing to gain a foothold. “Meanwhile in Q1, the company has made further advancements in its development of AVERSA, and it is maintaining…

MondayJun 03, 2024 3:22 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Reverse Stock Split

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-50 reverse split of its common stock, effective at 4:01 p.m. ET on June 4, 2024. According to the update, beginning on June 5, 2024, the company’s common stock will continue to trade on the Nasdaq Capital Market on a split adjusted basis under the trading symbol CNSP, but will trade under the following new CUSIP number: 18978H300. The move is primarily intended to increase CNSP’s share trading price and bring…

FridayMay 31, 2024 3:46 pm

BioMedNewsBreaks — Biomerica Inc. (NASDAQ: BMRA) Announces Agreement in $5.5M At-the-Market Offering

Biomerica (NASDAQ: BMRA), a biomedical technology company that develops, patents, manufactures and markets advanced diagnostics and therapeutic products, has entered into an at-market issuance sales agreement with EF Hutton LLC and R.F. Lafferty & Co. Inc. According to the company, the agreement is related to BMRA common stock shares. The company filed a prospectus supplement on May 10, 2024. EF Hutton is serving as sales agent to Biomerica in connection with the $5.5 million at-the-market offering. “In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock pursuant to this prospectus having…

FridayMay 31, 2024 2:25 pm

BioMedNewsBreaks — Why Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. “The company’s AVERSA(TM) can be incorporated into any transdermal patch and includes aversive agents to prevent misuse and accidental exposure to drugs with abuse potential, specifically opioids. AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia… Nutriband…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

BioMedNewsBreaks — Bluejay Diagnostics Inc. (NASDAQ: BJDX) Secures ~$2.2M in Private Placement

BioMedNewsBreaks — Astiva Health Inc. to Host Summer Gala

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Emerging Growth Conference

BioMedNewsBreaks — HealthLynked Corp. (HLYK) Receives $1M from CEO to Support Company’s Efforts to ‘Lead the Way’ to More Efficient Healthcare System

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Event Spotlighting Lead Drug Candidate

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Releases Q1 2024 Quarterly Report

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Reverse Stock Split

BioMedNewsBreaks — Biomerica Inc. (NASDAQ: BMRA) Announces Agreement in $5.5M At-the-Market Offering

BioMedNewsBreaks — Why Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search